**Summary of current COVID treatments & HIV-specific advice**

| DRUG | LICENSE | ART DDI | PREGNANCY | UK GUIDANCE |
|---|---|---|---|---|
| **Anti-IL-6 monoclonal antibodies** | | | | |
| Tocilizumab IV | Off-license | Nil expected | Risk of harm in animal studies; do not use unless clearly necessary | People **hospitalised** with hypoxaemia + raised CRP *or* requiring ventilatory support (high flow nasal oxygen, CPAP, NIV or IV regardless of CRP) |
| Sarilumab IV | Off-license | Nil expected | No/limited data, use only if benefits >risks | People **hospitalised** with hypoxaemia + raised CRP *or* requiring ventilatory support (high flow nasal oxygen, CPAP, NIV or IV regardless of CRP) when tocilizumab unavailable |
| **Anti-SARS-CoV-2 monoclonal antibodies (neutralising monoclonal antibodies or nMAB)** | | | | |
| Casirivimab + imdevimab IV (Ronapreve) | Prophylaxis and treatment of acute COVID-19 | Nil expected | No/limited data, use only if benefits >risks | Offer to all aged ≥12 years **hospitalised** due to COVID-19, SARS-CoV-2 seronegative AND local hospital Omicron variant prevalence <50% OR non-Omicron variant on genotyping. Consider for hospital-onset COVID-19 if non-Omicron variant AND 'highest risk' group OR other eligibility as per policy |
| Sotrovimab IV (Xevudy) | Symptomatic acute COVID-19 in people aged ≥12 years, not requiring oxygen at increased risk of severe infection | Nil expected | No data, use where expected benefit > risk | Hospitalised: as above where local hospital Omicron variant prevalence is 50% or more, or Omicron variant on genotyping. Non-hospitalised: as outlined above for people at higher risk. |
| **Antivirals** | | | | |
| Remdesevir IV | COVID-19 in people aged ≥12 years requiring oxygen | Nil expected | No/limited data, do not use unless clinically required | Consider up to 5 days for **hospitalised** people requiring oxygen; **Timing/dose/oxygenation status may vary if severely immunocompromised** (BHIVA advises CD4 <200, recent ADI, not on ART or detectable VL) |
| Molnupiravir PO (Lagevrio) | Mild/moderate COVID-19 in adults with at least one risk factor for severe illness | Low (not a substrate, inhibitor, or inducer of enzymes or transporters) | Reproductive toxicity in animal studies, **should not be used in pregnancy** | **PANORAMIC community-based trial** OR<br>Available through routine NHS care from 16th December 2021 for **non-hospitalised** people **at higher risk** with a positive SARS-CoV-2 PCR test and **not suitable for nMAB** |

**References:**

NICE COVID-19 rapid guideline: Managing COVID-19; v18.1 published 14/12/2021; NHS Interim clinical commissioning policy: Remdesivir for patients hospitalised with COVID-19 (adults and children 12 years and older) version 3, published 15 June 2021; NHS Interim Clinical Commissioning Policy: Neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19, published 16 December 2021, effective from 20 December 2021; NHS Interim Clinical Commissioning Policy: Neutralising monoclonal antibodies in the treatment of COVID-19 in non-hospitalised patients, published 16 December 2021, effective from 20 December 2021

References: NICE COVID-19 guidelines v18.1; NHS remdesivir policy 15/06/2021; NHS non-hospitalised nMAB & antiviral policy 16/12/2021; NHS hospitalised nMAB policy 16/12/2021